A functional assay–based procedure to classify mismatch repair gene variants in Lynch syndrome

PurposeTo enhance classification of variants of uncertain significance (VUS) in the DNA mismatch repair (MMR) genes in the cancer predisposition Lynch syndrome, we developed the cell-free in vitro MMR activity (CIMRA) assay. Here, we calibrate and validate the assay, enabling its integration with in silico and clinical data.MethodsTwo sets of previously classified MLH1 and MSH2 variants were selected from a curated MMR gene database, and their biochemical activity determined by the CIMRA assay. The assay was calibrated by regression analysis followed by symmetric cross-validation and Bayesian integration with in silico predictions of pathogenicity. CIMRA assay reproducibility was assessed in four laboratories.ResultsConcordance between the training runs met our prespecified validation criterion. The CIMRA assay alone correctly classified 65% of variants, with only 3% discordant classification. Bayesian integration with in silico predictions of pathogenicity increased the proportion of correctly classified variants to 87%, without changing the discordance rate. Interlaboratory results were highly reproducible.ConclusionThe CIMRA assay accurately predicts pathogenic and benign MMR gene variants. Quantitative combination of assay results with in silico analysis correctly classified the majority of variants. Using this calibration, CIMRA assay results can be integrated into the diagnostic algorithm for MMR gene variants.

[1]  Andrew J Vickers.  Decision Analysis for the Evaluation of Diagnostic Tests, Prediction Models, and Molecular Markers , 2008, The American statistician.

[2]  T. Slavin,et al.  Clinical Application of Multigene Panels: Challenges of Next-Generation Counseling and Cancer Risk Management , 2015, Front. Oncol..

[3]  Douglas F Easton,et al.  Genetic evidence and integration of various data sources for classifying uncertain variants into a single model , 2008, Human mutation.

[4]  A. Spurdle,et al.  Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results , 2008, Human mutation.

[5]  A. de la Chapelle,et al.  Functional significance and clinical phenotype of nontruncating mismatch repair variants of MLH1. , 2005, Gastroenterology.

[6]  F. Couch,et al.  The germline MLH1 K618A variant and susceptibility to Lynch syndrome-associated tumors. , 2012, Journal of Molecular Diagnostics.

[7]  Tina Pesaran,et al.  Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients , 2014, Genetics in Medicine.

[8]  A. de la Chapelle,et al.  Pathogenicity of MSH2 missense mutations is typically associated with impaired repair capability of the mutated protein. , 2006, Gastroenterology.

[9]  N. de Wind,et al.  A rapid and cell‐free assay to test the activity of lynch syndrome‐associated MSH2 and MSH6 missense variants , 2012, Human mutation.

[10]  Steven Gallinger,et al.  A Multifactorial Likelihood Model for MMR Gene Variant Classification Incorporating Probabilities Based on Sequence Bioinformatics and Tumor Characteristics: A Report from the Colon Cancer Family Registry , 2013, Human mutation.

[11]  Gene variants of unknown clinical significance in Lynch syndrome. An introduction for clinicians , 2013, Familial Cancer.

[12]  Christopher D. Heinen,et al.  Milestones of Lynch syndrome: 1895–2015 , 2015, Nature Reviews Cancer.

[13]  G. Chenevix-Trench,et al.  Growing recognition of the role for rare missense substitutions in breast cancer susceptibility. , 2014, Biomarkers in medicine.

[14]  M. Cowles.  Statistical Computing: An Introduction to Data Analysis using SPlus , 2004 .

[15]  Heidi L Rehm,et al.  ClinGen--the Clinical Genome Resource. , 2015, The New England journal of medicine.

[16]  A. Spurdle,et al.  The BRCA1 c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium , 2017, Journal of Medical Genetics.

[17]  Fergus J Couch,et al.  A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. , 2007, American journal of human genetics.

[18]  F. Couch,et al.  Classification of missense substitutions in the BRCA genes: A database dedicated to Ex‐UVs , 2012, Human mutation.

[19]  J. Trojan,et al.  Expression Defect Size among Unclassified MLH1 Variants Determines Pathogenicity in Lynch Syndrome Diagnosis , 2013, Clinical Cancer Research.

[20]  P. Modrich,et al.  Strand-specific mismatch correction in nuclear extracts of human and Drosophila melanogaster cell lines. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[21]  M. Greenblatt,et al.  Multi-gene panel testing for hereditary cancer susceptibility in a rural Familial Cancer Program , 2016, Familial Cancer.

[22]  Rodney J Scott,et al.  Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database , 2013, Nature Genetics.

[23]  Predrag Radivojac,et al.  Calibration of Multiple In Silico Tools for Predicting Pathogenicity of Mismatch Repair Gene Missense Substitutions , 2013, Human mutation.

[24]  L. Rasmussen,et al.  Approaches to diagnose DNA mismatch repair gene defects in cancer. , 2016, DNA repair.

[25]  H. Hotelling.  Applications of the Theory of Error to the Interpretation of Trends , 1929 .

[26]  N. de Wind,et al.  A cell‐free assay for the functional analysis of variants of the mismatch repair protein MLH1 , 2010, Human mutation.

[27]  R. Nussbaum,et al.  Modeling the ACMG/AMP Variant Classification Guidelines as a Bayesian Classification Framework , 2018, Genetics in Medicine.

[28]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[29]  Wendy K Chung,et al.  Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing , 2015, Genetics in Medicine.

[30]  Dubravka Georgijevic,et al.  Functional analysis of HNPCC-related missense mutations in MSH2. , 2008, Mutation research.

[31]  F. Couch,et al.  Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. , 2004, American journal of human genetics.

[32]  M. Drost,et al.  Inactivation of DNA Mismatch Repair by Variants of Uncertain Significance in the PMS2 Gene , 2013, Human mutation.

[33]  Christopher D. Heinen,et al.  Pathological assessment of mismatch repair gene variants in Lynch syndrome: Past, present, and future , 2012, Human mutation.